vimarsana.com
Home
Live Updates
FDA Grants Fast Track Designation to Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia : vimarsana.com
FDA Grants Fast Track Designation to Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
In December 2023, nipocalimab (Johnson & Johnson) was granted orphan drug designation for fetal neonatal alloimmune thrombocytopenia.
Related Keywords
,
Jacob Lund ,
Katie Abouzahr ,
Johnson ,
Janssen Research Development ,
Maternal Fetal Immunology Disease Area Leader ,
Severe Hemolytic Disease ,
Janssen Research ,
Breakthrough Therapy Designation ,
Rare Disease ,
vimarsana.com © 2020. All Rights Reserved.